Currently, breast cancer is clinicopathologically classified into four subtypes based on the expression of the HRs estrogen receptor (ER) and progesterone receptor (PR), expression of human epidermal growth factor 2 (HER2), and on the proliferative index Ki-67. This evidence concerns the gene ERBB2 and breast carcinoma.